Table 3 Serum OS markers at baseline and on the trigger day.

From: Growth hormone alleviates oxidative stress and improves oocyte quality in Chinese women with polycystic ovary syndrome: a randomized controlled trial

 

PCOS-T (n = 50)

PCOS-C (n = 50)

Non-PCOS (n = 50)

Baseline

Trigger day

Change

Baseline

Trigger day

Change

Baseline

Trigger day

Change

MDA (µmol/L)

4.87 ± 0.95

5.08 ± 1.24

0.20 ± 0.48

4.71 ± 1.02

5.13 ± 1.02

0.42 ± 0.24

4.67 ± 1.02

4.70 ± 0.78

0.33 ± 0.29

SOD (U/mg prot)

14.22 ± 1.39

15.23 ± 2.56

1.02 ± 1.20

14.49 ± 1.92

14.96 ± 1.89

0.47 ± 0.56

14.23 ± 2.04

15.11 ± 2.23

0.89 ± 0.63

TAC (mmol Trolox Eq/L)a

0.70 ± 0.15

0.62 ± 0.15

-0.08 ± 0.06

0.72 ± 0.10

0.60 ± 0.17

-0.11 ± 0.08

0.70 ± 0.11

0.59 ± 0.19

-0.11 ± 0.08

TOS (µmol H2O2 Eq/L)a

19.71 ± 7.96

24.05 ± 9.82

4.34 ± 2.99

19.40 ± 7.27

24.24 ± 10.09

4.85 ± 3.69

15.15 ± 5.89

22.83 ± 7.98

7.68 ± 3.21

OSIa

29.02 ± 11.76

39.18 ± 13.58

10.15 ± 7.75

27.29 ± 9.81

42.97 ± 17.09

15.68 ± 11.91

21.60 ± 7.57

40.78 ± 12.80

16.18 ± 9.23

  1. Data are presented as mean ± SD.
  2. MDA malondialdehyde, SOD superoxide dismutase, TAC total antioxidant capacity, TOS total oxidant status, OSI oxidative stress index.
  3. aP < 0.05 parameter on the trigger day versus baseline.
Back to article page